A comparative analysis of remdesivir and other repurposed antivirals against SARS-CoV-2.

EMBO Mol Med · 2021 · PMC7646058 · PMID 33015938

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

not yet significantno p-value reported

However, in a subgroup of patients that were treated with RDV within 10 days of symptom onset there was a numerical reduction of five days in time to clinical improvement that was not yet significant (hazard ratio 1.52 [95% CI: 0.95–2.43]) (Wang et al , 2020c ).

also in 316 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.